# Innovative Technologies for the Treatment of Pulmonary and Heart Failure

> **NCT05090930** · NA · UNKNOWN · sponsor: **National Research Center for Cardiac Surgery, Kazakhstan** · enrollment: 100 (estimated)

## Conditions studied

- Cardiogenic Shock
- Ventricular Arrythmia
- Cardiac Arrest With Successful Resuscitation
- Sepsis
- Multiple Organ Failure
- Pulmonary Failure
- Decompensated Heart Failure
- Acute Heart Failure

## Interventions

- **DEVICE:** HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
- **DEVICE:** CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber

## Key facts

- **NCT ID:** NCT05090930
- **Lead sponsor:** National Research Center for Cardiac Surgery, Kazakhstan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05090930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05090930, "Innovative Technologies for the Treatment of Pulmonary and Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05090930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*